Publication: 3166

Publication: 3166

Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Ther Adv Med Oncol vol 12

Year:: 2020
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 9

Parents:: 549 574 589 642
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Bayer; Genentech
Grants:: U10CA180821, U10CA180882, UG1CA232760, UG1CA189808, U24CA196171

Corr. Author:
Authors:: Hao Xie Jacqueline M. Lafky Bruce W. Morlan Philip J. Stella Shaker R. Dakhil Gerald G. Gross William S. Loui Joleen M. Hubbard Steven R. Alberts Axel Grothey

Networks:: HAWAII, KS055, LAPS-MN026, MCRC, METROMIN, SANFORD

Study: NCCTG-N054C
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: antiangiogenesis, bevacizumab, colorectal cancer, single nucleotide polymorphism, sorafenib